Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06922994

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Led by Centro Cardiologico Monzino · Updated on 2025-07-03

102

Participants Needed

5

Research Sites

87 weeks

Total Duration

On this page

Sponsors

C

Centro Cardiologico Monzino

Lead Sponsor

F

Federico II University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if Atorvastatin 80 mg is effective to avoid functional right ventricular deterioration in patients affected by Arrhythmogenic Cardiomyopathy. It will also learn about the safety of Atorvastatin 80 mg in this type of patients. The main questions it aims to answer are: 1. Does Atorvastatin 80 mg prevent worstening of the right ventricular functioning? 2. Does Atorvastatin 80 mg prevent the worsening of electric, morphological and biomarkers deterioration? 3. What medical problems do participants have when taking Atorvastatin 80 mg? Researchers will compare Atorvastatin 80 mg to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat Arrhythmogenic Cardiomyopathy. Participants will: 1. Take Atorvastatin 80 mg or a placebo every day for 18 months; 2. Visit the clinic at the enrollment and after 2, 4, 9 and 18 months for checkups and tests; 3. Make a phone call for safety check after 12, 15 and 19 months since the enrollment; 4. Fill out psychological questionnaires

CONDITIONS

Official Title

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must be at least 18 years of age at the time of signing the informed consent
  • Participants affected by Arrhythmogenic Cardiomyopathy as defined by task force criteria
Not Eligible

You will not qualify if you...

  • Known hypersensitivity to atorvastatin or any of the excipients
  • Moderate or severe liver disease
  • Muscle disease
  • Left ventricular ejection fraction less than 35%
  • Congestive heart failure defined by New York Heart Association (NYHA) class III or IV
  • Known cardiomyopathy of other origin including post ischemic, hypertrophic, idiopathic dilated, restrictive
  • Known moderate-to-severe mitral or aortic valvulopathy
  • Pulmonary hypertension
  • Congenital cardiac abnormalities
  • Hypercholesterolemic patients requiring lipid lowering drugs
  • Heart transplantation
  • Estimated life expectancy less than 2 years
  • Any medical condition that places the patient at risk, makes them unreliable, or limits study completion
  • Use of potent CYP3A4 modifiers such as Erythromycin, Clarithromycin, Azole antifungals, Protease inhibitors, Gemfibrozil, Ciclosporin, Danazol
  • Use of Fusidic acid
  • Use of Hepatitis C antivirals like telaprevir, boceprevir, glecaprevir/pibrentasvir, ledipasvir/sofosbuvir
  • Use of other lipid lowering drugs such as Statins, Cholesterol absorption inhibitors, Bile acid sequestrants, PCSK9 inhibitors, ATP-citrate lyase inhibitors, Fibrates, Omega-3 fatty acid ethyl esters
  • Use of drugs primarily indicated as antioxidants
  • Enrollment in another clinical trial or past trial with investigational drug within 30 days or 5 half-lives
  • Pregnant or lactating women
  • Women of childbearing age not using adequate contraception
  • Known dependency on alcohol or drug abuse
  • Contraindications to cardiac magnetic resonance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Fondazione I.R.C.C.S. Policlinico San Matteo

Pavia, PV, Italy, 27100

Actively Recruiting

2

Università Politecnica delle Marche

Ancona, Italy, 60126

Actively Recruiting

3

Centro Cardiologico Monzino IRCSS

Milan, Italy, 20138

Actively Recruiting

4

AORN - Ospedali dei Colli

Naples, Italy, 80131

Actively Recruiting

5

Università degli Studi di Napoli Federico II

Naples, Italy, 80138

Not Yet Recruiting

Loading map...

Research Team

E

Elena Sommariva

CONTACT

C

Claudio Tondo

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here